MX2015007753A - Composicion de vacunas para sujetos intactos. - Google Patents

Composicion de vacunas para sujetos intactos.

Info

Publication number
MX2015007753A
MX2015007753A MX2015007753A MX2015007753A MX2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A
Authority
MX
Mexico
Prior art keywords
vaccine
vaccine composition
subjects
naive subjects
directed
Prior art date
Application number
MX2015007753A
Other languages
English (en)
Inventor
Hans Arwidsson
Anna-Karin Maltais
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of MX2015007753A publication Critical patent/MX2015007753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a composiciones de vacunas administradas por vía nasal eficaces en sujetos intactos tales como los niños. Además, la composición de vacuna es adecuada para la vacunación de la población en general durante una pandemia. Un aspecto de la invención se dirige al uso pediátrico de la vacuna de la invención que incluye una vacuna eficaz en los niños contra cepas del virus de la influenza estacional. Un aspecto adicional de la invención se dirige a los sujetos de todos los grupos de edad cuando la composición es para su uso pandémico.
MX2015007753A 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos. MX2015007753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
MX2015007753A true MX2015007753A (es) 2016-01-08

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Country Status (12)

Country Link
US (2) US11065325B2 (es)
EP (4) EP2742952A1 (es)
JP (3) JP2016502997A (es)
KR (3) KR20150132093A (es)
CN (3) CN104884085A (es)
AU (2) AU2013360890B2 (es)
BR (2) BR112015014243A8 (es)
CA (2) CA2895028A1 (es)
HK (2) HK1212611A1 (es)
MX (2) MX2015007688A (es)
RU (2) RU2661408C2 (es)
WO (2) WO2014095944A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607792A (en) * 2010-09-30 2015-08-28 Eurocine Vaccines Ab Improved vaccine compositions
HUE060456T2 (hu) * 2014-09-26 2023-03-28 Seqirus Uk Ltd Immunkompromittált alanyok oltása
EP3197487B1 (en) 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
US20200306364A1 (en) * 2017-11-30 2020-10-01 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
CA3180165A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
EP4135519A1 (en) * 2020-04-16 2023-02-22 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
EP4135521A1 (en) * 2020-04-16 2023-02-22 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
WO2023133342A2 (en) * 2022-01-10 2023-07-13 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
EP1372528B1 (en) 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
ATE480258T1 (de) 2002-11-26 2010-09-15 Eurocine Vaccines Ab Neue adjuvant auf der basis von aminen
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
EP1910387B1 (en) 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
JP5028627B2 (ja) 2005-08-05 2012-09-19 国立大学法人徳島大学 ＩｇＡ抗体の選択的産生からＩｇＡ及びＩｇＧ両抗体産生への切換えを可能にする抗原薬物ビークルとこれを用いる経鼻・粘膜ワクチン
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2010033274A2 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
ES2618576T3 (es) 2009-05-28 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
NZ607792A (en) 2010-09-30 2015-08-28 Eurocine Vaccines Ab Improved vaccine compositions

Also Published As

Publication number Publication date
JP2019112448A (ja) 2019-07-11
AU2013360890A1 (en) 2015-07-02
AU2013360890B2 (en) 2017-04-13
HK1213492A1 (zh) 2016-07-08
CN104884085A (zh) 2015-09-02
WO2014095944A1 (en) 2014-06-26
CA2895028A1 (en) 2014-06-26
RU2661408C2 (ru) 2018-07-16
KR20210007042A (ko) 2021-01-19
US20150306205A1 (en) 2015-10-29
RU2661407C2 (ru) 2018-07-16
CN104870010A (zh) 2015-08-26
BR112015014243A2 (pt) 2017-07-11
EP2931307A1 (en) 2015-10-21
EP2931308B1 (en) 2018-10-10
RU2015129077A (ru) 2017-01-23
KR20150132092A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
HK1212611A1 (zh) 2016-06-17
JP2016502997A (ja) 2016-02-01
EP2931308A1 (en) 2015-10-21
AU2013360889B2 (en) 2016-12-01
BR112015014174A2 (pt) 2017-07-11
JP2016502996A (ja) 2016-02-01
EP3431101A1 (en) 2019-01-23
RU2015129028A (ru) 2017-01-23
CA2895023A1 (en) 2014-06-26
AU2013360889C1 (en) 2017-06-08
CN112826929A (zh) 2021-05-25
AU2013360889A1 (en) 2015-07-02
KR20150132093A (ko) 2015-11-25
MX2015007688A (es) 2015-09-07
US20150306204A1 (en) 2015-10-29
BR112015014243A8 (pt) 2019-10-08
EP2742952A1 (en) 2014-06-18
US11065325B2 (en) 2021-07-20
WO2014095943A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
PH12015501482A1 (en) Nasal influenza vaccine composition
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
EA201290956A1 (ru) Вакцина против вич
PH12016501968A1 (en) Novel macrocyclic compounds
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
AU2011280259A8 (en) Influenza vaccine
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2013173256A3 (en) New and improved influenza vaccines
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención